Takeda sets sights on obesity with global Amylin tie-up
This article was originally published in Scrip
Takeda is taking a decisive step into the obesity sector through a wide-ranging global alliance with Amylin Pharmaceuticals, which could eventually be worth more than $1 billion to the US firm.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.